510(k) · Cleared
ClearedUlthera® System
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Ulthera, Inc. · OHV Focused Ultrasound For Tissue Heat Or Mechanical Cellular Disruption
Cleared on May 21, 2026 as substantially equivalent to K250418 (Ulthera, Inc., 2025) after an 85-day review. Its family tree reaches back 8 generations to 1989.
- Decided
- May 21, 2026
- Review
- 85 days
- Class
- Class II
- Product code
- OHV
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 8 generations to K894834 (1989). 10 ancestors in all. No later device cites it as a predicate yet.
- Root · 8 generations backK894834 Dermascan C, an Ultrasonic Diagnostic SystemBrymill Corp. · 1989
- 7 generations backK983945 Cortex Dermascan C Ultrasonic SystemCortex Technology Aps · 1999
- 6 generations backK132028 Ulthera SystemUlthera, Inc. · 2013
- 5 generations backK134032 Ulthera SystemUlthera, Inc. · 2014
- 4 generations backK180623 Ulthera SystemUlthera, Inc. · 2018
- 3 generations backK233996 Ulthera System (UC-1 Control Unit PRIME)Ulthera, Inc. · 2024
- 2 generations backK243035 Ulthera® SystemUlthera, Inc. · 2025
- 1 generation backK250418 Ulthera System (UC-1 Control Unit PRIME Model 2.1)Ulthera, Inc. · 2025
- This deviceK260618 Ulthera® SystemUlthera, Inc. · 2026
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −8 | K894834 | Dermascan C, an Ultrasonic Diagnostic System | Brymill Corp. | 1989 | — |
| −7 | K983945 | Cortex Dermascan C Ultrasonic System | Cortex Technology Aps | 1999 | — |
| −6 | K132028 | Ulthera System | Ulthera, Inc. | 2013 | — |
| −5 | K134032 | Ulthera System | Ulthera, Inc. | 2014 | — |
| −4 | K180623 | Ulthera System | Ulthera, Inc. | 2018 | — |
| −3 | K233996 | Ulthera System (UC-1 Control Unit PRIME) | Ulthera, Inc. | 2024 | — |
| −2 | K243035 | Ulthera® System | Ulthera, Inc. | 2025 | — |
| −1 | K250418 | Ulthera System (UC-1 Control Unit PRIME Model 2.1) | Ulthera, Inc. | 2025 | — |
| 0 (this device) | K260618 | Ulthera® System | Ulthera, Inc. | 2026 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2009 | 1 | 0 |
| 2012 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in OHV? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new OHV device
- #1 K250418 Ulthera System (UC-1 Control Unit PRIME Model…score 14.1 · 7 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K250418 | Ulthera System (UC-1 Control Unit PRIME Model 2.1)Summary page 5…Clearance of Diagnostic Ultrasound Systems and Transducers 3 PREDICATE DEVICE Ulthera® System (UC-1 Control Unit PRIME), Ulthera, Inc., K250418 Page 1 of 5 Ulthera… | 2025 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 37 years and passes through 3 companies; a new generation was cleared every 3.9 years on median.
- None of the 10 ancestors has a recall.
How does its category compare?
All OHV devicesOHV Focused Ultrasound For Tissue Heat Or Mechanical Cellular Disruption: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.
FDA decisions per year · OHV
2in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · OHV
90in 2023
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · OHV
1in 2023
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · OHV
20in 2025
MAUDE reports naming product code OHV, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 1 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 2 | — | 0 | 0 |
| 2012 | 2 | — | 0 | 1 |
| 2013 | 1 | — | 0 | 18 |
| 2014 | 3 | 171 | 0 | 17 |
| 2015 | 0 | — | 0 | 19 |
| 2016 | 3 | 107 | 0 | 29 |
| 2017 | 1 | — | 0 | 29 |
| 2018 | 1 | — | 0 | 10 |
| 2019 | 2 | — | 0 | 15 |
| 2020 | 0 | — | 0 | 6 |
| 2021 | 1 | — | 0 | 11 |
| 2022 | 1 | — | 0 | 12 |
| 2023 | 7 | 90 | 1 | 11 |
| 2024 | 2 | — | 0 | 11 |
| 2025 | 2 | — | 0 | 20 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
The Ulthera® System is intended to apply focused ultrasound energy to the body to achieve temporary changes in the physical appearance of the skin. The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to: • lift the eyebrow • lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental and neck regions • improve lines and wrinkles of the décolleté. •…
Read the full statement (155 words)
The Ulthera® System is intended to apply focused ultrasound energy to the body to achieve temporary
changes in the physical appearance of the skin.
The Ulthera® System is indicated for use as a non-invasive dermatological aesthetic treatment to:
• lift the eyebrow
• lift lax submental (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in
the submental and neck regions
• improve lines and wrinkles of the décolleté.
• improve the appearance of skin laxity on the abdomen, anterior arms, posterior arms, and knees
The Ulthera® System in conjunction with the Ulthera® DeepSEE transducer allows for ultrasonic
visualization of depths up to 8 mm below the surface of the skin. The indicated use of the imaging is to
visualize the dermal and subdermal layers of tissue to:
• ensure proper coupling of the transducer to the skin
• confirm appropriate depth of treatment such as to avoid bone
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K260618 · printed Nov 6, 2026
Cite this page
510(k) Report. “K260618: Ulthera® System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K260618
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded Oct 30, 2026
- Summary read Oct 30, 2026 (extraction version 2d9447fa9ea4)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026